Want to see ZYME full AI Analyst Report?
ZYME Stock Chart & Stats
$27.47
$0.14(0.61%)
At close: 4:00 PM EDT
$27.47
$0.14(0.61%)
Day’s Range― - ―
52-Week Range$16.00 - $31.34
Previous Close$23
Volume259.30K
Average Volume (3M)931.17K
Market Cap
$1.79B
Enterprise Value$1.91B
Total Cash (Recent Filing)$270.70M
Total Debt (Recent Filing)$268.64M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 09, 2026EPS Estimate
2.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding70,959,240
10 Day Avg. Volume1,273,353
30 Day Avg. Volume931,174
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.39
Price to Sales (P/S)18.72
P/FCF Ratio-57.45
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue51.34
Enterprise Value/Gross Profit58.49
Enterprise Value/Ebitda-13.59
Forecast
1Y Price Target
$40.83Price Target Upside48.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)1.04
Revenue Forecast (FY)$296.53M
Bulls Say, Bears Say
Bulls Say
Revenue DiversificationThe completed Theravance transaction broadens Zymeworks beyond clinical-stage development by adding YUPELRI profit-sharing and royalty streams. This diversification can create recurring funding for R&D and reduce dependence on sporadic licensing milestones over the next several quarters.
Cash PositionA $322.5 million cash position provides meaningful financial capacity for clinical development, partnerships and other strategic initiatives. That liquidity can help sustain investment in the pipeline and support operations while the company transitions toward more diversified revenue sources.
Proprietary Platform And PipelineZymeworks’ proprietary antibody engineering platforms provide a technology base for developing multispecific therapeutics across oncology and other severe diseases. A platform approach can support multiple programs and partnerships, creating opportunities for milestone, licensing and royalty income.
Bears Say
Persistent Cash BurnContinued negative operating and free cash flow means the business is not yet self-funding and must rely on its cash balance, financing or partner payments. Persistent cash consumption can constrain R&D flexibility and increase dependence on successful pipeline or licensing milestones.
Revenue And Profitability WeaknessA sharp TTM revenue decline combined with recurring losses weakens the company’s earnings base and makes operating performance dependent on uneven deals or milestones. Sustained losses can limit internal reinvestment and increase the importance of successful commercialization and partnerships.
Secured Debt BurdenThe new secured financing adds fixed interest obligations and places first-priority liens on substantially all assets of guaranteed entities. Its covenants and change-of-control protections may limit financial flexibility, while repayment obligations increase execution risk during the integration period.
Zymeworks News
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $16.00 and its highest was $31.34 in the past 12 months.
What is Zymeworks Inc’s market cap?
Zymeworks Inc’s market cap is $1.79B.
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is Nov 09, 2026 which is in 20 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on Aug 06, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.575 by -$0.045.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is 2.26.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 70,959,240 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.575. Following the earnings report the stock price went up 1.773%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Currently, no hedge funds are holding shares in ZYME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.83 (48.65% Upside)
$40.83 (48.65% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 78%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 343.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.93%
12-Months-Change
Fundamentals
Return on Equity
-72.07%
Trailing 12-Months
Asset Growth
-2.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zymeworks Inc
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
ZYME Stock 12 Month Forecast
Average Price Target
$40.83
▲(48.65% Upside)
Technical Analysis
Xencor
―
AnaptysBio
―
Vir Biotechnology
―
AbCellera Biologics
―
Generate Biomedicines, Inc.
―
Ownership Overview
1.34% Insiders
8.71% Mutual Funds
2.31% Other Institutional Investors
78.75% Public Companies and
Individual Investors